Neuromuscular

The trial is anticipated to enroll 300 patients with amyotrophic lateral sclerosis in Europe to evaluate the safety and efficacy of oral edaravone.

Data suggest the need to investigate sleep-disordered breathing even before lung function is compromised in patients with cystic fibrosis.

The PHOENIX study is a follow-up study to CENTAUR, a phase 2/3 study that demonstrated AMX0035’s ability to improve survival rate in patients with ALS.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 5, 2021.

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Through 36 weeks of treatment with CNM-Au8, investigators observed a slowing of disease progression and decreased number of participants with a 6-point decline on ALSFRS-R.

Investigators interviewed 20 community neurologists about the impact of the pandemic on their professional and personal lives, finding 4 main themes among their responses.

In a phase 2/3 setting, AMX0035 demonstrated a 44% lower risk of death for patients with ALS compared to those who started on placebo.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 29, 2021.

ALSFRS-R and FVC values were stable after cell therapy during the 3-month follow-up; however, the scores and values significantly decreased after 6 months of treatment. The data, the authors noted, warrant future assessments in ALS.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

Investigators found that women with early-onset myasthenia gravis display distinct clinical features in contrast with men with the same condition, who are more like patients with late-onset MG of both sexes.

Treatment of ALS with tofersen resulted in differences in total cerebrospinal fluid SOD1 protein and neurofilament light chain, both markets of target engagement and neuronal degeneration.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Clinical data on the investigational therapeutics, DNL343 and SAR443820/DNL788, were presented at the 2021 Annual Northeast ALS Meeting this month.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

The organization called attention to unintended harms of the current Medicare benefit structure and the need for the Center for Medicare & Medicaid Services to be more “patient-focused” in its assessments.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Here's what is coming soon to NeurologyLive.

In preclinical mouse models lacking both dystrophin and utrophin, treatment with an agent using the company's PN chemistry resulted in 100% survival at 40 weeks, setting up the therapy for this phase 1b2/a trial.

Findings from studies of the neuromuscular treatments were presented by at the 2021 World Muscle Society Virtual Congress, September 20-24.

Neurology News Network for the week of October 2, 2021. [WATCH TIME: 4 minutes]

Patients with Duchenne muscular dystrophy receiving the treatment had a decline in Mid-level Performance of Upper Limb scores in the phase 2 trial of the cell therapy.